|
1
|
Wei WI and Sham JS: Nasopharyngeal
carcinoma. Lancet. 365:2041–2054. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Du M, Chen W, Zhang W, Tian XK, Wang T, Wu
J, Gu J, Zhang N, Lu ZW, Qian LX, et al: TGF-? regulates the
ERK/MAPK pathway independent of the SMAD pathway by repressing
miRNA-124 to increase MALAT1 expression in nasopharyngeal
carcinoma. Biomed Pharmacother. 99:688–696. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Wang Y, Zhang Y and Ma S: Racial
differences in nasopharyngeal carcinoma in the United States.
Cancer Epidemiol. 37:793–802. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Lee AWM, Tung SY, Ng WT, Lee V, Ngan RKC,
Choi HCW, Chan LLK, Siu LL, Ng AWY, Leung TW, et al: A multicenter,
phase 3, randomized trial of concurrent chemoradiotherapy plus
adjuvant chemotherapy versus radiotherapy alone in patients with
regionally advanced nasopharyngeal carcinoma: 10-year outcomes for
efficacy and toxicity. Cancer. 123:4147–4157. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Lee V, Kwong D, Leung TW, Lam KO, Tong CC
and Lee A: Palliative systemic therapy for recurrent or metastatic
nasopharyngeal carcinoma-How far have we achieved? Crit Rev Oncol
Hematol. 114:13–23. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Chan AT: Nasopharyngeal carcinoma. Ann
Oncol. 21 Suppl 7:vii308–vii312. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Gao W, Chan JY and Wong TS: Differential
expression of long noncoding RNA in primary and recurrent
nasopharyngeal carcinoma. Biomed Res Int. 2014:4045672014.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Wang YN, Shan K, Yao MD, Yao J, Wang JJ,
Li X, Liu B, Zhang YY, Ji Y, Jiang Q and Yan B: Long noncoding
RNA-GAS5: A novel regulator of hypertension-induced vascular
remodeling. Hypertension. 68:736–748. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Zhang D, Cao C, Liu L and Wu D:
Up-regulation of LncRNA SNHG20 predicts poor prognosis in
hepatocellular carcinoma. J Cancer. 7:608–617. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Li C, Zhou L, He J, Fang XQ, Zhu SW and
Xiong MM: Increased long noncoding RNA SNHG20 predicts poor
prognosis in colorectal cancer. BMC Cancer. 16:6552016. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Wu Y, Shen Z, Wang K, Ha Y, Lei H, Jia Y,
Ding R, Wu D, Gan S, Li R, et al: High FMNL3 expression promotes
nasopharyngeal carcinoma cell metastasis: Role in TGF-β1-induced
epithelia-to-mesenchymal transition. Sci Rep. 7:425072017.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Schwarzenbach H, Hoon DS and Pantel K:
Cell-free nucleic acids as biomarkers in cancer patients. Nat Rev
Cancer. 11:426–437. 2011. View
Article : Google Scholar : PubMed/NCBI
|
|
14
|
Cho WC: Nasopharyngeal carcinoma:
Molecular biomarker discovery and progress. Mol Cancer. 6:12007.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Bianchessi V, Badi I, Bertolotti M, Nigro
P, D'Alessandra Y, Capogrossi MC, Zanobini M, Pompilio G, Raucci A
and Lauri A: The mitochondrial lncRNA ASncmtRNA-2 is induced in
aging and replicative senescence in endothelial cells. J Mol Cell
Cardiol. 81:62–70. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Lu L, Xu H, Luo F, Liu X, Lu X, Yang Q,
Xue J, Chen C, Shi L and Liu Q: Epigenetic silencing of miR-218 by
the lncRNA CCAT1, acting via BMI1, promotes an altered cell cycle
transition in the malignant transformation of HBE cells induced by
cigarette smoke extract. Toxicol Appl Pharmacol. 304:30–41. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Kryger RL, Fan L, Jaquet V and Wilce PA:
Identification of a ncRNA which is elevated in brain of human
alcoholics and alcohol-treated rats. Alcohol Clin Exp Res.
30:152A2006.
|
|
18
|
Yin JJ, Selander K, Chirgwin JM, Dallas M,
Grubbs BG, Wieser R, Massagué J, Mundy GR and Guise TA: TGF-beta
signaling blockade inhibits PTHrP secretion by breast cancer cells
and bone metastases development. J Clin Invest. 103:197–206. 1999.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Muraoka RS, Dumont N, Ritter CA, Dugger
TC, Brantley DM, Chen J, Easterly E, Roebuck LR, Ryan S, Gotwals
PJ, et al: Blockade of TGF-beta inhibits mammary tumor cell
viability, migration, and metastases. J Clin Invest. 109:1551–1559.
2002. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Siegel PM and Massagué J: Cytostatic and
apoptotic actions of TGF-beta in homeostasis and cancer. Nat Rev
Cancer. 3:807–821. 2003. View
Article : Google Scholar : PubMed/NCBI
|
|
21
|
Yang YA, Dukhanina O, Tang B, Mamura M,
Letterio JJ, MacGregor J, Patel SC, Khozin S, Liu ZY, Green J, et
al: Lifetime exposure to a soluble TGF-β antagonist protects mice
against metastasis without adverse side effects. J Clin Invest.
109:1607–1615. 2002. View Article : Google Scholar : PubMed/NCBI
|
